ELAN

Elanco Animal Health Incorporated

$26.76

-0.30%
SectorHealthcareIndustryDrug Manufacturers - Specialty & GenericCountryUnited States

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.

Source: Yahoo Finance
AI summary

Price & performance

1M-0.2%
3M-9.1%
YTD+0.0%
1Y+3.4%
52-week range—
Beta1.29
Full chart and returns against a benchmark

Q-Score

63/ 100

Quality against peers; 50 is the peer median.

Growth57
Risk67
Performance62
Valuation61
Profitability60
Leverage41
Sentiment49
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$4.7B+6.2%
Net income-$232M-168.6%
Net margin-4.9%-12.5 pts
Historical fundamentals

Revenue exposure

53%of revenue from outside the US
Non-US53%
United States47%
Largest customer12%
Regions, segments, customers and suppliers

Valuation

ELANIndustryP/E—35.25P/S2.602.74EV/EBITDA—16.35P/B2.022.46PEG—0.87
Dividend yield0.00%
Every valuation metric

Earnings

Nov 6next report, before the open
EPS estimate$0.21
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate